Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

Overall survival and progression-free survival outcomes appear similar for lutetium-177 and actinium-225 in select patients with mCRPC, with some differences between radioligand therapies.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug Administration (FDA) for expanded prostate cancer use.

The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of ...